Bristol-Myers Squibb Company

BMY

US1101221083

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.

Sector

Pharmaceuticals

Calendar

26/07/2024 - Q2 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology

January 09, 2024 at 11:36 pm IST

More Strategies

Ratings for Bristol-Myers Squibb Company

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

40.97 USD

Average target price

53.19 USD

Spread / Average Target

+29.84%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BRISTOL-MYERS SQUIBB COMPANY	-19.86%	8.31TCr
ELI LILLY AND COMPANY	+51.94%	80TCr
NOVO NORDISK A/S	+40.60%	63TCr
JOHNSON & JOHNSON	-6.69%	35TCr
MERCK & CO., INC.	+17.15%	32TCr
ABBVIE INC.	+11.02%	30TCr
ASTRAZENECA PLC	+17.13%	24TCr
ROCHE HOLDING AG	+0.98%	22TCr
AMGEN INC.	+6.09%	16TCr
PFIZER, INC.	-5.54%	15TCr

Other Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 07:28:47 18/06/2024 pm IST			5-day change	1st Jan Change
40.72 ^USD	-0.60%		-4.42%	-19.86%

03:41pm	Bristol Myers Squibb Keeps Quarterly Dividend at $0.60 a Share, Payable Aug. 1 to Shareholders of Record July 5	MT
01:26pm	Bristol Myers: Board declares dividend	CF

Bristol Myers Squibb Keeps Quarterly Dividend at $0.60 a Share, Payable Aug. 1 to Shareholders of Record July 5	07:11pm	MT
Bristol Myers: Board declares dividend	04:56pm	CF
Bristol Myers Squibb Declares A Quarterly Dividend, Payable on August 1, 2024	04:29pm	CI
Bristol Myers: FDA approval for treatment	14/06	CF
Bristol-Myers Squibb's Augtyro Gets FDA Accelerated Approval for Treatment of Solid Tumors	14/06	MT
Bristol Myers Squibb's Augtyro Gets FDA Accelerated Approval	14/06	DJ
Bristol Myers Squibb Announces U.S. Food and Drug Administration Approves Augtyro (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors	14/06	CI
Evotec to Receive $20 Million Under Neuroscience Partnership with Bristol Myers Squibb	12/06	MT
Evotec Gets $20 Million Milestone Payment in Neurodegenerative Disease Collaboration With Bristol Myers Squibb	12/06	MT
Evotec Announces Progress in Neuroscience Collaboration with Bristol Myers Squibb	12/06	CI
Transcript : Bristol-Myers Squibb Company Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 11:20 AM	11/06
ABL Bio, BMS Collaborate on Gastric Cancer Treatment Trial	10/06	MT
Geron shares surge after U.S. FDA approves blood disorder drug	07/06	RE
I-Mab Collaborates With Bristol-Myers to Evaluate Givastomig in Combination Study for Gastric, Esophageal Cancers	05/06	MT
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers	05/06	CI
Bristol-Myers Squibb Says Opdivo Plus Yervoy Therapy Improves Survival of Liver Cancer Patients	04/06	MT
Bristol Myers: positive results in liver cancer	04/06	CF
Bristol Myers Squibb Announces Opdivo Plus Yervoy Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carinoma in Checkmate -9DW Trial	04/06	CI
Envisagenics, Inc. announced that it has received $25 million in funding from New York City Economic Development Corporation, Third Kind Venture Capital, Red Cell Management, LLC, Bristol-Myers Squibb Company	04/06	CI
Bristol-Myers Squibb Says Breyanzi Studies Show 'Meaningful' Outcomes Across B-cell Malignancies	03/06	MT
Bristol Myers Squibb?S Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented At 2024 Asco® Annual Meeting	03/06	CI
Bristol Myers: presents advances in lung cancer	03/06	CF
Bristol Myers Squibb Presents Multiple New Analyses At 2024 Asco® Annual Meeting Highlighting Opdivo and Opdivo-Based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer	03/06	CI
Pre-surgery treatment with Bristol Myers combination therapy leads to better skin cancer outcomes	02/06	RE
GSK blood cancer drug nearly halves risk of death in late-stage trial	02/06	RE